Abstracts tagged "prevention"

Abstract Number: 2558 • ACR Convergence 2023
Aortic Aneurysms in a Multicenter Cohort of 196 Patients with Aortitis Related to Giant Cell Arteritis Treated with Tocilizumab
Fernando López¹, Javier Loricera², Adrián Martín-Gutiérrez³, Carmen Secada³, Santos Castañeda⁴, Clara Moriano Morales⁵, Javier Narvaez⁶, Vicente Aldasoro⁷, Olga Maiz⁸, Rafael Benito Melero-Gonzalez⁹, PALOMA VELA¹⁰, Susana Romero Yuste¹¹, Eugenio De Miguel¹², Eva Galindez-Agirregoikoa¹³, Jesús Carlos Fernández López¹⁴, Ivan Ferraz Amaro¹⁵, Julio Sánchez-Martín³, Jose L. Callejas¹⁶, Patricia Moya Albarado¹⁷ and Ricardo Blanco¹⁸, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Rheumatology, Hospital Universitario de León, León, Spain, ⁶Hospital Universitario de Bellvitge, Barcelona, Spain, ⁷Hospital Universitario de Navarra, Pamplona, Spain, ⁸Hospital Universitario de Donostia. San Sebastián, Spain., Donosti, Spain, ⁹CHU Vigo, O Carballino, Spain, ¹⁰Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ¹¹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Basurto University Hospital, Bilbao, Spain, ¹⁴Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain, ¹⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ¹⁶Unit of Systemic Autoimmune Diseases, Hospital San Cecilio, Granada, Spain, ¹⁷Hospital Universitario de Sant Pau, Barcelona, Spain, ¹⁸Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Aortic aneurysms is a serious complication that can occur in patients with giant cell arteritis (GCA) (1-2). Tocilizumab (TCZ) is approved for GCA. Nevertheless,…
Abstract Number: 0198 • ACR Convergence 2023
Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership
Stephen Lindsey¹, Brittany Hill², Sheela Sheth³ and Arya Loghmani², ¹LSU Health Science Center, New Orleans, LA, ²Louisiana State University, New Orleans, LA, ³Tulane University, New Orleans, LA
Background/Purpose: Herpes zoster (HZ), also known as shingles, causes an estimated one million cases annually in the United States. Many studies have shown that the…
Abstract Number: 1099 • ACR Convergence 2023
Improving Hydroxychloroquine Dosing and Eye Screening Compliance in Patients with Connective Tissue Disorder
Maria Salgado Guerrero¹ and Angelo Gaffo², ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, AL; Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Hydroxychloroquine (HCQ) is a key treatment for patients with lupus and other rheumatic diseases. To minimize the risk of retinal toxicity, the American College…
Abstract Number: 2581 • ACR Convergence 2023
Proteomic Signatures in Pre-Rheumatoid Arthritis Suggest Evolving Biological Pathways in Different Stages of Disease Development That May Inform Prediction and Prevention Strategies
Samir Rachid Zaim¹, Adam Savage¹, Mark Gillespie¹, Christy Bennett¹, lynne Becker¹, LauraKay Moss², Marie Feser², Jess Edison³, Ted R Mikuls⁴, Michael Holer², kevin Deane² and Xiao-Jun Li¹, ¹Allen Institute for Immunology, Seattle, WA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³Walter Reed Military Medical Center, Bethesda, MD, ⁴Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) includes a stage of development that can be termed 'pre-RA' and defined as the presence of abnormal biomarkers and/or other features…
Abstract Number: 0203 • ACR Convergence 2023
Projecting the Impact on Clinical Outcomes in ANCA-Associated Vasculitis of Delaying Retreatment with Rituximab for Vaccine Optimization
Zachary Wallace¹, Aaron Wu², Shruthi Srivatsan², Naomi Patel², Jeffrey Sparks³, Eli Miloslavsky², Hyon K. Choi⁴, Peter Merkel⁵, John Stone⁶ and Emily Hyle², ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Rituximab (RTX) is effective for maintaining remission in ANCA-associated vasculitis (AAV) but increases risks for vaccine-preventable severe infections and reduces the immune response to…
Abstract Number: 1351 • ACR Convergence 2023
HPV Vaccination in Adolescent and Young Adult Patients Seen in an Academic Rheumatology Center
Caroline Siegel¹, Lauren Robinson¹, Deanna Jannat-Khah¹, Avi Mikhaylov¹, Nancy Pan¹ and Lisa Sammaritano², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Adolescent and young adults (AYAs) with rheumatic disease (RD) may face disproportionate risk of HPV and associated cancers due to immune dysregulation, immunosuppression and…
Abstract Number: 2584 • ACR Convergence 2023
Gut Microbiome and Intestinal Inflammation in Preclinical Stages of Rheumatoid Arthritis
Benoît Thomas P. GILBERT¹, Raul Yhossef TITO TADEO², Céline LAMACCHIA¹, Olivia STUDER¹, Delphine COURVOISIER¹, Jeroen RAES³ and Axel Finckh⁴, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven, Leuven, Belgium, ³Center for Microbiology, VIB, Leuven. Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, Katholieke Universiteit Leuven., Leuven, Belgium, ⁴HUG, Geneva, Switzerland
Background/Purpose: We attempted to replicate and expand previous findings of an increased abundance of Prevotellaceae in early untreated Rheumatoid Arthritis (RA) or its preclinical stages,…
Abstract Number: 0208 • ACR Convergence 2023
Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System
Angela Bobak¹, Emely Pimentel¹, Jordan Jackson², Celia Gray³, Hema Srinivasan³, Andrea Berger³ and David Bulbin³, ¹Geisinger Medical Center Internal Medicine Residency, Danville, PA, ²Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, ³Geisinger Health System, Danville, PA
Background/Purpose: PJP is an opportunistic fungus causing significant morbidity and mortality in immunocompromised patients. Guidelines describe PJP PPX indications among non-HIV infected individuals with cancer…
Abstract Number: 1387 • ACR Convergence 2023
Power Doppler Musculoskeletal Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis
Rebecca Haberman¹, Sarah Moussavi¹, Yan Zhang¹, Sydney Catron¹, Jonathan Samuels², Rebecca Blank³, Michael Toprover⁴, Jiyuan Hu¹, Cinty Gong⁵, Vincent Piguet⁶, Francisco Tausk⁷, Jensen Yeung⁸, Andrea Neimann¹, Wayne Gulliver⁹, Joseph Merola¹⁰, Alexis R Ogdie¹¹, Proton Rahman¹², Soumya Chakravarty¹³, Ralf Thiele¹⁴, Lihi Eder¹⁵, Christopher T Ritchlin¹⁶ and Jose Scher¹⁷, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone, Rye Brook, NY, ³New York University, New York, NY, ⁴New York University Langone Health, New York, NY, ⁵Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, USA, Raritan, NJ, ⁶Women's College Hospital, Toronto, ON, Canada, ⁷University of Rochester Medical Center, Rochester, NY, ⁸University of Toronto and Women’s College Hospital, Toronto, ON, Canada, ⁹Memorial University of Newfoundland, St. John's, NL, Canada, ¹⁰Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ¹³Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, ¹⁴University of Rochester, Pittsford, NY, ¹⁵Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ¹⁶University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, ¹⁷New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated disease associated with skin psoriasis that, if untreated, can lead to joint destruction. Up to 30% of patients…
Abstract Number: 2585 • ACR Convergence 2023
Cytokine and Chemokine Elevations in ACPA+ Individuals Suggest Possible Viral, Mucosal and/or Innate Responses Are Related to the Transition to Future Clinical RA
Daniel Carlson¹, Charles Carpenter², Salina Goff¹, Jennifer Seifert¹, LauraKay Moss¹, Marie Feser¹, Jane Buckner³, William H. Robinson⁴, Jessica Kirschmann⁴, Gary Firestein⁵, Michael Holer¹ and Kevin Deane¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²Colorado School of Public Health, Aurora, CO, ³Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁴Stanford University, Palo Alto, CA, ⁵University of California San Diego, San Diego, CA

Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period definable as elevations of antibodies to citrullinated protein antibodies (ACPA) before clinically-apparent inflammatory arthritis (i.e. Clinical RA).…
Abstract Number: 0209 • ACR Convergence 2023
Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
Hilde Ørbo¹, Ingrid Jyssum¹, Anne Therese Tveter¹, Ingrid Christensen¹, Joseph Sexton¹, Kristin Hammersbøen Bjørlykke², Grete B. Kro³, Tore Kvien¹, Gunnveig Grødeland⁴, Ludvig A. Munthe⁵, Siri Mjaaland⁶, John Torgils Vaage⁵, Espen Haavardsholm¹, Kristin Kaasen Jørgensen², Sella Provan⁷, Silje Watterdal Syversen¹ and Guro Goll¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Department of Microbiology, Oslo University Hospital, Oslo, Norway, ⁴Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁵Department of Immunology, Oslo University Hospital, Oslo, Norway, ⁶Norwegian Institute of Public Health, Oslo, Norway, ⁷Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…
Abstract Number: 1801 • ACR Convergence 2023
Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study
Ioanna Minopoulou¹, Koray Tascilar², Giulia Corte¹, Melek Yalcin Mutlu¹, Katja Schmidt², Daniela Bohr¹, Fabian Hartmann², Bernhard Manger², Arnd Kleyer³, David Simon¹, Thomas Harrer², Georg Schett⁴ and Filippo Fagni¹, ¹Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³University Hospital Erlangen, Erlangen, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) and particularly those treated with B-cell-depleting agents frequently fail to develop humoral responses to SARS-CoV-2 vaccinations and have…
Abstract Number: 0217 • ACR Convergence 2023
Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study
Tali Eviatar¹, Victoria Furer², Ilana Kaufman³, David levartovsky², Ofir Elalouf², Devy Zisman⁴, Tal Gazitt⁵, Amir Haddad⁴, Muna Elias⁶, Joy Feld⁷, Alexandra Balbir-Gurman⁸, Yolanda Braun Moscovici⁹, Sara Pel¹⁰, sharon Nevo¹¹, Daphna Paran² and Ori Elkayam², ¹Tel Aviv Sourasky Medical center, Ramat Gan, Israel, ²Tel Aviv Medical Center, Tel Aviv, Israel, ³Tel Aviv Medical Center, Petah-Tikva, Israel, ⁴Carmel Medical Center, Haifa, Israel, ⁵Carmel Hospital, Haifa, Israel, ⁶rheumatology unit, Haifa, Israel, ⁷Carmel and Zvulun Medical Centre, Haifa, Israel, ⁸Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ⁹Rambam Heath Care Campus, Haifa, Israel, ¹⁰Tel Aviv Medical Center, Modiin, Israel, ¹¹Tel Aviv Sourasky Medical Center, Givataim, Israel
Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
Abstract Number: 1848 • ACR Convergence 2023
Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease
Caroline Siegel¹, Lauren Robinson¹, Deanna Jannat-Khah¹, Avi Mikhaylov¹, Nancy Pan¹ and Lisa Sammaritano², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: The HPV vaccine is safe and immunogenic in RD patients but uptake is suboptimal. We aimed to evaluate factors associated with HPV vaccination in…
Abstract Number: 0219 • ACR Convergence 2023
Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab
Savino Sciascia¹, MARIA LETIZIA RILAT², ROBERTA FENOGLIO², SILVIA GRAZIETTA FODDAI³, MASSIMO RADIN³, IRENE CECCHI³, giacoma cinnirella², paola crosasso², maria gabriella guidetti², ALICE BARINOTTI³, simone baldovino², ELISA MENEGATTI⁴ and Dario Roccatello⁵, ¹University of Turin, Torino, Italy, ²University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy, ³University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, ⁴School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, ⁵University of Torino, Torino, Italy
Background/Purpose: Patients on B-cell depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting SARS-CoV-2 or suffering from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].